Sunlenca Product Label
Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 2
Mechanism
Inhibition of CYP3A4 by lenacapavir
Clinical Effects
Potential increased risk of bleeding
Management
Use with caution. Monitor for rivaroxaban adverse effects (e.g. bleeding). Avoid coadministration in persons with renal impairment (CrCL 15 - 80 ml/min) due to increased risk of bleeding.
Info Source
